Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -199 | -122 | 17 | 752 | 662 |
| Depreciation Amortization | 79 | 54 | 27 | 108 | 82 |
| Accounts receivable | 638 | 526 | 330 | 579 | -199 |
| Accounts payable and accrued liabilities | -769 | -636 | -209 | -1,181 | -788 |
| Other Working Capital | 93 | -213 | -78 | -862 | -1,224 |
| Other Operating Activity | 233 | 157 | -125 | 613 | 993 |
| Operating Cash Flow | $75 | $-234 | $-38 | $9 | $-474 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -37 | -34 | -32 | -3 | -2 |
| Purchase Of Investment | -398 | -405 | -172 | -516 | -432 |
| Sale Of Investment | N/A | N/A | N/A | 6 | 6 |
| Other Investing Activity | 35 | 19 | 7 | 22 | 14 |
| Investing Cash Flow | $-401 | $-419 | $-197 | $-491 | $-414 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -34 | -34 | N/A | -26 | -21 |
| Common Stock Issued | 150 | 150 | N/A | N/A | N/A |
| Other Financing Activity | -6 | -4 | 0 | -2 | -2 |
| Financing Cash Flow | $110 | $112 | $N/A | $-28 | $-23 |
| Exchange Rate Effect | -447 | -243 | -45 | -154 | -176 |
| Beginning Cash Position | 2,124 | 2,124 | 2,124 | 2,788 | 2,788 |
| End Cash Position | 1,462 | 1,340 | 1,844 | 2,124 | 1,700 |
| Net Cash Flow | $-662 | $-784 | $-280 | $-664 | $-1,087 |
| Free Cash Flow | |||||
| Operating Cash Flow | 75 | -234 | -38 | 9 | -474 |
| Capital Expenditure | -37 | -34 | -32 | -3 | -2 |
| Free Cash Flow | 38 | -267 | -70 | 6 | -476 |